In 2021, M&A activity in the biopharma sector saw a paradoxical trend: while companies had unprecedented financial capacity, the total number of acquisitions declined. Partnerships slightly decreased from 2020's record levels, yet the sector remained attractive, with stock price premiums averaging 62%, and up to 150% for innovative cell therapies.Similarly, the MedTech industry experienced a resurgence, with M&A deal values reaching $111 billion by November, the highest since 2014. This surge is attributed to a combination of substantial financial resources and shifts in care models due to the pandemic, particularly in remote monitoring technologies.
